How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer

BMC Cancer

Kaaren J Watts¹  Bettina Meiser¹  Gillian Mitchell²  Judy Kirk⁷  Christobel Saunders⁸  Michelle Peate¹  Jessica Duffy⁵  Patrick J Kelly⁴  Margaret Gleeson³  Kristine Barlow-Stewart⁶  Belinda Rahman⁵  Michael Friedlander¹  Kathy Tucker⁵ 

[1] Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Kensington, NSW, 2052, Australia

[2] Peter MacCallum Cancer Centre, Familial Cancer Service, Locked Bag 1, A'Beckett Street, East Melbourne, VIC, 8006, Australia

[3] Hunter Family Cancer Service, PO Box 84, Waratah, NSW, 2298, Australia

[4] School of Public Health, The University of Sydney, Edward Ford Building, Sydney, NSW, 2006, Australia

[5] Department of Medical Oncology, Prince of Wales Hospital, High Street, Randwick, NSW, 2031, Australia

[6] Centre for Genetics Education, PO Box 317, St Leonards, NSW, 1590, Australia

[7] Westmead Millennium Institute for Medical Research at the University of Sydney, PO Box 412, Westmead, NSW, 2145, Australia

[8] Department of Surgery, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia

关键词: Clinical practice;    Treatment;    BRCA2;    BRCA1;    Genetic testing;    Breast cancer;   

Others  :  1080287
DOI  :  10.1186/1471-2407-12-320

 received in 2012-07-04, accepted in 2012-07-13,  发布年份 2012

【 摘 要 】

Background

Germline BRCA1 and BRCA2 mutation testing offered shortly after a breast cancer diagnosis to inform women’s treatment choices - treatment-focused genetic testing ‘TFGT’ - has entered clinical practice in specialist centers and is likely to be soon commonplace in acute breast cancer management, especially for younger women. Yet the optimal way to deliver information about TFGT to younger women newly diagnosed with breast cancer is not known, particularly for those who were not suspected of having a hereditary breast cancer syndrome prior to their cancer diagnosis. Also, little is known about the behavioral and psychosocial impact or cost effectiveness of educating patients about TFGT. This trial aims to examine the impact and efficiency of two models of educating younger women newly diagnosed with breast cancer about genetic testing in order to provide evidence for a safe and effective future clinical pathway for this service.

Design/methods

In this non-inferiority randomized controlled trial, 140 women newly diagnosed with breast cancer (aged less than 50 years) are being recruited from nine cancer centers in Australia. Eligible women with either a significant family history of breast and/or ovarian cancer or with other high risk features suggestive of a mutation detection rate of > 10% are invited by their surgeon prior to mastectomy or radiotherapy. After completing the first questionnaire, participants are randomized to receive either: (a) an educational pamphlet about genetic testing (intervention) or (b) a genetic counseling appointment at a family cancer center (standard care). Each participant is offered genetic testing for germline BRCA mutations. Decision-related and psychosocial outcomes are assessed over 12 months and include decisional conflict (primary outcome);uptake of bilateral mastectomy and/or risk-reducing salpingo-oophorectomy; cancer-specific- and general distress; family involvement in decision making; and decision regret. A process-oriented retrospective online survey will examine health professionals’ attitudes toward TFGT; a health economic analysis will determine the cost effectiveness of the intervention.

Discussion

This trial will provide crucial information about the impact, efficiency and cost effectiveness of an educational pamphlet designed to inform younger women newly diagnosed with breast cancer about genetic testing. Issues regarding implementation of the trial are discussed.

Trial registration

The study is registered with the Australian and New Zealand Clinical Trials Group (Registration no: ACTRN12610000502033)

【 授权许可】

   
2012 Watts et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

Figure 4 .

【 参考文献 】

• [1]Tung N: Management of women with BRCA mutations: A 41-year-old woman with a BRCA mutation and a recent history of breast cancer. JAMA 2011, 305:2211-2220.
• [2]Pierce LJ, Phillips K-A, Griffith KA, Buys S, Gaffney DK, Moran MS, Haffty BG, Ben-David M, Kaufman B, Garber JE, Merajver SD, Balmana J, Meirovitz A, Domchek SM: Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: Comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010, 121:389-398.
• [3]Evans DGR, Moran A, Hartley R, Dawson J, Bulman B, Knox F, Howell A, Lalloo F: Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. Br J Cancer 2010, 102:1091-1098.
• [4]Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA: Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2011, 104:1384-1392.
• [5]Heemskerk-Gerritsen B: Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival [abstract]? Eur J Cancer 2010, 8:s206.
• [6]McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC: Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001, 19:3938-3943.
• [7]Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW: Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project. J Clin Oncol 2005, 23:4275-4286.
• [8]Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304:967-975.
• [9]Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25:1329-1333.
• [10]Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch HT, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR: Risk-reducing oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J Clin Oncol 2008, 26:1331-1337.
• [11]Klee E, Hoppman-Chaney N, Ferber M: Expanding DNA diagnostic panel testing: Is more better? Expert Rev Mol Diagn 2011, 11:703-709.
• [12]Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010, 376:235-244.
• [13]Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL: The role of poly adenosine disphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions. Asia-Pac J Clin Onco 2011, 7:197-211.
• [14]Ardern-Jones A, Kenen R, Eeles R: Too much too soon? Patients' and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care 2005, 14:272-281.
• [15]Schwartz MD, Lerman C, Brogan B, Peshkin BN, Hughes Halbert C, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, Pennanen M, Tsangaris T, Willey S, Isaacs C: Impact of BRCA1/2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004, 22:1823-1829.
• [16]Schwartz MD, Lerman C, Brogan B, Peshkin BN, Isaacs C, DeMarco T, Hughes Halbert C, Pennanen M, Finch C: Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev 2005, 14:1003-1007.
• [17]Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, Magnant CM, Rogers S, Isaacs C, Schwartz MD: Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol 2007, 25:285-291.
• [18]Schlich-Bakker KJ, Wárlám-Rodenhuis CC, van Echtelt J, van den Bout J, Ausems MG, ten Kroode HF: Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur J Cancer 2006, 42:2722-2728.
• [19]Wevers MR, Ausems MG, Verhoef S, Bleiker EMA, Hahn DEE, Hogervorst FBL, van der Luijt RB, Valdimarsdottir HB, van Hillegersberg R, Rutgers EJ, Aaronson NK: Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: Design of a multicenter randomized clinical trial. BMC Cancer 2011, 11:6. BioMed Central Full Text
• [20]Møller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, Løvslett K, Hovig E, Vabø A: Genetic epidemiology of BRCA mutations - family history detects less than 50% of the mutation carriers. Eur J Cancer 2007, 43:1713-1717.
• [21]de Sanjosé S, Léoné M, Bérez V, Izquierdo A, Font R, Brunet JM, Louat T, Vilardell L, Borras J, Viladiu P, Bosch FX, Lenoir GM, Sinilnikova OM: Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: A population-based study. Int J Cancer 2003, 106:588-593.
• [22]Myriad for Professionals: BRCA1 and BRCA2 Prevalence Tables. https://www.myriadpro.com/bracanalysis-prevalence-tables webcite
• [23]Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, Glentis S, Bournakis E, Bobos M, Pectasides D, Papakostas P, Pentheroudakis G, Gogas H, Skarlos P, Samantas E, Bafaloukos D, Kosmidis PA, Koutras A, Yannoukakos D, Konstantopoulou I, Fountzilas G: Prevalence of BRCA1 mutations among 403 women wtih triple-negative breast cancer: Implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2012, 134:353-262. E-Pub 21 March 2012
• [24]Australian Institute of Health and Welfare: ACIM (Australian Cancer Incidence and Mortality) Books. AIHW, Canberra; 2011.
• [25]Narod SA: BRCA mutations in the management of breast cancer: the state of the art. Nature Rev Clin Oncol 2010, 7:702-707.
• [26]Zilliacus E, Meiser B, Gleeson M, Watts K, Tucker K, Lobb EA, Mitchell G: Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer. Support Care Cancer 2012. E-Pub 24 March 2012
• [27]Meiser B, Gleeson M, Watts K, Peate M, Zilliacus E, Barlow-Stewart K, Saunders C, Mitchell G, Kirk J: Getting to the point: What women newly diagnosed with breast cancer want to know about treatment-focused genetic testing. Oncol Nurs Forum 2012, 39:E101-E111.
• [28]Royal Australasian College of Surgeons National Breast Cancer Audit. http://www.surgeons.org/for-health-professionals/audits-and-surgical-research/morbidity-audits/nbca/ webcite
• [29]Schulz KF, Altman DG, Moher D, for the CONSORT Group: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010, 152:726-732.
• [30]Breheny N, Geelhoed E, Goldblatt J, O'Leary P: Cost-effectiveness of predictive genetic tests for familial breast and ovarian cancer. Genomics, Society and Policy 2005, 1:67-79.
• [31]National Breast and Ovarian Cancer Centre: Advice about familial aspects of breast cancer and epithelial ovarian cancer: a guide for health professionals. Sydney; 2010.
• [32]O'Connor AM: Validation of a decisional conflict scale. Med Decis Making 1995, 15:25-30.
• [33]O'Connor AM: User Manual - Decisional Conflict Scale. http://decisionaid.ohri.ca/eval_dcs.html webcite
• [34]Thewes B, Meiser B, Hickie IB: Psychometric properties of the Impact of Event Scale amongst women at increased risk for hereditary breast cancer. Psycho-Oncology 2001, 10:459-468.
• [35]Ibbotson T, Maguire P, Selby P, Priestman T, Wallace L: Screening for anxiety and depression in cancer patients: the effects of disease and treatment. Eur J Cancer 1994, 30A:37-40.
• [36]O'Connor AM, Cranney A: User Manual - Acceptability. http://decisionaid.ohri.ca/eval_accept.html webcite
• [37]Cella D, Hughes C, Peterman A, Chang CH, Peshkin BN, Schwartz MD, Wenzel L, Lemke A, Marcus AC, Lerman C: A brief assessment of concerns associated with genetic testing for cancer: The Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol 2002, 21:564-572.
• [38]Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, Feldman-Stewart D: Validation of a decision regret scale. Med Decis Making 2003, 23:281-292.
• [39]O'Connor A: User Manual - Decision Regret Scale. http://decisionaid.ohri.ca/eval_regret.html webcite
• [40]Thewes B, Meiser B, Duric VM, Stockler MR, Taylor A, Stuart-Harris R, Links M, Wilcken N, MacLachlan SA, Phillips KA, Beith J, Boyle F, Friedlander ML: What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 2005, 6:581-588.
• [41]Watts K, Meiser B, Conlon H, Rovelli S, Tiller K, Zorbas H, Lewis C, Neil G, Friedlander M: A specialist breast care nurse role for women with metastatic breast cancer: Enhancing supportive care. Oncol Nurs Forum 2011, 38:627-631.
• [42]Beacon HJ, Thompson SG: Multi-level models for repeated measurement data: Application to quality of life data in clinical trials. Stat Med 1996, 15:2717-2732.
• [43]Zilliacus EM, Meiser B, Lobb EA, Kelly PJ, Barlow-Stewart K, Kirk JA, Spigelman AD, Warwick LJ, Tucker KM: Are videoconferenced consultations as effective as face-to-face consultations for hereditary breast and ovarian cancer genetic counseling? Genet Med 2011, 13:933-941.
• [44]Kerber RA, Slartery ML: Comparison of self-reported and database-linked family history of cancer data in a case–control study. Am J Epidemiol 1997, 146:244-248.